Until recently, there was no FDA-approved treatment in the United States for hepatorenal syndrome, a major complication of advanced liver disease. Patients with hepatorenal syndrome develop acute kidney failure, and often require dialysis. After more than a decade of research, in September 2022 the FDA granted approval to terlipressin, a medication that can reverse kidney failure in these patients, quickly establishing terlipressin as the routinely prescribed medication.

Read more